Through the various investment vehicles managed by Sightline Partners and 10K Lakes Capital, we have had the opportunity to invest in high-quality companies across the healthcare space. Here is a subset of Sightline Partners’ portfolio companies that have completed and/or announced successful exits through M&A or IPO.
Acquired By Boston Scientific in 2011
Atritech’s WATCHMAN® Left Atrial Appendage Closure Technology is the first FDA-approved device to offer an alternative to anticoagulant drugs for patients experiencing atrial fibrillation who are at high risk for stroke. In 2011, Boston Scientific acquired Atritech for total consideration of up to $375 million.
Acquired by Vertex Pharma in 2019
Semma’s proprietary cell therapy technology has the potential to transform the treatment of diabetes in insulin dependent patients. The company focuses on using stem-cell derived human islets as a possible cure for type 1 diabetes. In 2019, Vertex Pharma acquired Semma for total consideration of $950 million.
NASDAQ: ACCD IPO in 2020
Accolade provides personalized health and benefit solutions designed to help millions of people and their employers navigate the complexities of the healthcare system while lowering the cost of care and improving health outcomes. In 2020, Accolade raised $220 million in an initial public offering and is listed on the NASDAQ under the ticker symbol ACCD.
Acquired By Werfen in 2017
Accriva is a leader in point-of-care (PoC) diagnostics for coagulation. Accriva’s suite of PoC diagnostic tests help to improve decision making regarding coagulation and platelet aggregation in a way that optimizes treatment outcomes and the overall cost of hospital treatments. In 2017, Werfen acquired Accriva for total consideration of up to $380 million.
NASDAQ: SWAV IPO in 2019
Shockwave is a medical device company that engages in developing and commercializing intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. In 2019, Shockwave raised $97 million in an initial public offering.
NASDAQ: LYRA IPO in 2020
Lyra Therapeutics, a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. In 2020, Lyra raised $56 million in an initial public offering and is listed on the NYSE under the ticker symbol LYRA.
NYSE: VAPO IPO in 2018
Vapotherm, Inc. is a global medical technology company focused on the development and commercialization of its high velocity nasal insufflations (Hi-VNI) technology products used to treat patients suffering from respiratory distress. In 2018, Vapotherm raised $56 million in an IPO and is listed on the NYSE under the ticker symbol VAPO.
Acquired by Zoll Medical in 2021
Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, including sleep apnea. In December 2021, Itamar Medical was acquired by Zoll Medical for $538 million.
Acquired by Alcon in 2019
PowerVision is a clinical-stage ophthalmology company that develops a fluid-based intraocular lens that uses the eye’s natural accommodating response to transport fluid to the implanted lens. In 2019, Alcon acquired PowerVision for an upfront consideration of $275 million, plus additional regulatory and commercial milestone payments.